Initiate Sera Prognostics with a Hold rating due to strong clinical data, but uncertain commercialization timeline for PreTRM Test. Stock volatility in 2025, with shares dropping from $7.50 to $3.25 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results